Literature DB >> 8943052

A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.

A R Amin1, M G Attur, G D Thakker, P D Patel, P R Vyas, R N Patel, I R Patel, S B Abramson.   

Abstract

Tetracyclines have recently been shown to have "chondroprotective" effects in inflammatory arthritides in animal models. Since nitric oxide (NO) is spontaneously released from human cartilage affected by osteoarthritis (OA) or rheumatoid arthritis in quantities sufficient to cause cartilage damage, we evaluated the effect of tetracyclines on the expression and function of human OA-affected nitric oxide synthase (OA-NOS) and rodent inducible NOS (iNOS). Among the tetracycline group of compounds, doxycycline > minocycline blocked and reversed both spontaneous and interleukin 1 beta-induced OA-NOS activity in ex vivo conditions. Similarly, minocycline > or = doxycycline inhibited both lipopolysaccharide- and interferon-gamma-stimulated iNOS in RAW 264.7 cells in vitro, as assessed by nitrite accumulation. Although both these enzyme isoforms could be inhibited by doxycycline and minocycline, their susceptibility to each of these drugs was distinct. Unlike acetylating agents or competitive inhibitors of L-arginine that directly inhibit the specific activity of NOS, doxycycline or minocycline has no significant effect on the specific activity of iNOS in cell-free extracts. The mechanism of action of these drugs on murine iNOS expression was found to be, at least in part, at the level of RNA expression and translation of the enzyme, which would account for the decreased iNOS protein and activity of the enzyme. Tetracyclines had no significant effect on the levels of mRNA for beta-actin and glyceraldehyde-3-phosphate dehydrogenase nor on levels of protein of beta-actin and cyclooxygenase 2 expression. These studies indicate that a novel mechanism of action of tetracyclines is to inhibit the expression of NOS. Since the overproduction of NO has been implicated in the pathogenesis of arthritis, as well as other inflammatory diseases, these observations suggest that tetracyclines should be evaluated as potential therapeutic modulators of NO for various pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943052      PMCID: PMC19486          DOI: 10.1073/pnas.93.24.14014

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein.

Authors:  D J Stuehr; H J Cho; N S Kwon; M F Weise; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  Joint destruction in arthritis: metalloproteinases in the spotlight.

Authors:  C E Brinckerhoff
Journal:  Arthritis Rheum       Date:  1991-09

3.  Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action.

Authors:  L M Golub; H M Lee; G Lehrer; A Nemiroff; T F McNamara; R Kaplan; N S Ramamurthy
Journal:  J Periodontal Res       Date:  1983-09       Impact factor: 4.419

4.  Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems.

Authors:  L M Golub; J M Goodson; H M Lee; A M Vidal; T F McNamara; N S Ramamurthy
Journal:  J Periodontol       Date:  1985-11       Impact factor: 6.993

5.  Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody.

Authors:  A Svetić; F D Finkelman; Y C Jian; C W Dieffenbach; D E Scott; K F McCarthy; A D Steinberg; W C Gause
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

6.  How does interleukin 1 activate cells? Interleukin 1 signal transduction.

Authors:  L A O'Neill; T A Bird; J Saklatvala
Journal:  Immunol Today       Date:  1990-11

Review 7.  Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.

Authors:  L M Golub; N S Ramamurthy; T F McNamara; R A Greenwald; B R Rifkin
Journal:  Crit Rev Oral Biol Med       Date:  1991

8.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

9.  The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux.

Authors:  K L Sewell; F Breedveld; E Furrie; J O'Brien; C Brinckerhoff; R Dynesius-Trentham; Y Nosaka; D E Trentham
Journal:  Cell Immunol       Date:  1996-02-01       Impact factor: 4.868

10.  Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory.

Authors:  S Ehlers; K A Smith
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  103 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

2.  The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury.

Authors:  Dong Charn Cho; Jin Hwan Cheong; Moon Sul Yang; Se Jin Hwang; Jae Min Kim; Choong Hyun Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

3.  Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).

Authors:  Sara A Colopy; Theresa A Baker; Peter Muir
Journal:  J Am Vet Med Assoc       Date:  2010-02-01       Impact factor: 1.936

4.  Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF.

Authors:  O Saito; C I Svensson; M W Buczynski; K Wegner; X-Y Hua; S Codeluppi; R H Schaloske; R A Deems; E A Dennis; T L Yaksh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

6.  Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-κB/iNOS/NO-dependent cardiomyocyte contractile depression and death.

Authors:  Tadashi Yoshida; Nitin A Das; Andrea J Carpenter; Reza Izadpanah; Senthil A Kumar; Sandeep Gautam; Shawn B Bender; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2020-06-15       Impact factor: 4.315

Review 7.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

Review 8.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

9.  A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

Authors:  L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

10.  A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.

Authors:  Laura Orio; Noemi Llopis; Elisa Torres; Maria Izco; Esther O'Shea; M Isabel Colado
Journal:  Neurotox Res       Date:  2009-09-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.